Harjeet Singh, Ph.D.
Department of Pediatrics, Division of Pediatrics
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Assistant Professor, Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Postgraduate Training
| 2006-2008 | Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2004-2006 | Research Fellowship, City of Hope Cancer Center & Beckman Research Institute, Duarte, California |
| 2002-2004 | Research Fellowship, City of Hope Cancer Center & Beckman Research Institute, Duarte, California |
Experience & Service
Faculty Academic Appointments
Instructor, Department of Pediatrics - Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2019
Other Professional Positions
Research Investigator, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2016
Intramural Institutional Committee Activities
Immunology Program Admission Sub-Committee, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Extramural Institutional Committee Activities
Immunology Program Admission Committee, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Pebbles Task Force (Pediatrics), The University of Texas MD Anderson Cancer Center, 2023 - Present
Team Leader, Non-neural Solid Tumor Multidisciplinary Team, The University of Texas MD Anderson Cancer Center, 2021 - Present
Team Leader, Pediatrics Stem Cell Transplantation & Immunotherapy Multidisciplinary Team, The University of Texas MD Anderson Cancer Center, 2021 - Present
Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2019 - 2025
Member, Capital Equipment Committee (Pediatrics Research), The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Research Animal Care Committee (RACC), City of Hope/Beckman Research Institute, 2005
Editorial Activities
Associate Editor, Cancer Immunity and Immunotherapy, 2021 - Present
Review Editor, Frontiers in Immunology, 2016 - Present
Review Editor, Frontiers in Oncology, 2016 - Present
Honors & Awards
| 2013 | Performance Award for Dedication and Teamwork, The University of Texas MD Anderson Cancer Center |
| 2010 | Performance Award for Mentoring, The University of Texas MD Anderson Cancer Center |
| 2008 | Travel Award, World Imaging Congress |
| 2008 | Bristol-Myers Squibb Poster Award, The University of Texas MD Anderson Cancer Center |
| 2008 | Kimberly Patterson Fellowship in Leukemia Research |
| 2006 | Travel Award, American Society of Hematology |
| 2006 | New Investigator Travel Grant, BMT Tandem Meetings |
| 2005 | Developmental Research Grant Award, City of Hope Lymphoma Spore |
| 2003 | J Mitra Memorial Award, Indian Journal of Gastroenterology |
| 2001 | Best Paper Award, Indian National Association for Study of the Liver |
| 1999 | Best Poster Award, Symposium Biological Chemistry Beyond 2000 |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2019. Genetic modification of T cells to express CD19-specific CAR in two days. Conference. Genetic modification of T cells to express CD19-specific CAR in two days. San Francisco, CA, US.
- 2018. Sleeping Beauty: An update on the non-viral transduction platform for CAR therapies. Conference. Sleeping Beauty: An update on the non-viral transduction platform for CAR therapies. San Francisco, CA, US.
- 2015. Engineering T cells for one and all. Conference. Engineering T cells for one and all. Boston, MA, US.
- 2015. Democratizing gene therapy through the genetic manipulation of T cells. Conference. Democratizing gene therapy through the genetic manipulation of T cells. West Palm Beach, FL, US.
- 2015. The commercialization of T-cell therapies. Conference. The commercialization of T-cell therapies. Houston, TX, US.
- 2012. Reprogramming of T cells for improved therapeutic potential. Conference. Reprogramming of T cells for improved therapeutic potential. Lost Pines, TX, US.
- 2009. Genetically Engineered CD56-specific T Cells for the Treatment of Recurrent Neuroblastoma. Poster. National Harbor, MD, US.
- 2006. Non-invasive PET imaging of T cells derived from umbilical cord blood. Conference. Non-invasive PET imaging of T cells derived from umbilical cord blood. Keystone, CO, US.
- 2005. Combining Immunocytokine With Adoptive Immunotherapy To Treat B-Lineage Lymphomas. Conference. Combining Immunocytokine With Adoptive Immunotherapy To Treat B-Lineage Lymphomas. Atlanta, GA, US.
- 2003. Contribution of BCR Y177 ABL C-Terminal Sequences to BCR/ABL-Induced Transformation of Human Hematopoietic Progenitors. Conference. Contribution of BCR Y177 ABL C-Terminal Sequences to BCR/ABL-Induced Transformation of Human Hematopoietic Progenitors. San Diego, CA, US.
International Presentations
- 2015. The right patient for the right therapy. Conference. The right patient for the right therapy. Mainz, DE.
Formal Peers
- 2019. Reprogramming T cells for enhanced persistence. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2026 - 2027 |
| Title: | Click-Activated Antibody–Drug Conjugates to Potentiate γδ T-Cell Immunotherapy in Osteosarcoma |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2026 - 2027 |
| Title: | Engineering CAR T Cells Secreting Immunostimulatory Peptides to Reprogram the Tumor Microenvironment in Acute Myeloid Leukemia |
| Funding Source: | CPRIT MIRA (MDACC-UH) Pilot Project |
| Role: | PI |
| Date: | 2026 |
| Title: | Programmable Allogeneic CAR T cells to overcome immune rejection and suppression in osteosarccoma |
| Funding Source: | CPRIT MIRA |
| Role: | PI |
| Date: | 2026 |
| Title: | B-cell Mediated Immune Reprogramming Following Combined LSD1 and EGFR Inhibition in Glioblastoma |
| Funding Source: | Brain SPORE Career Enhancement Project |
| Role: | PI |
| Date: | 2026 |
| Title: | Neuronal Lineage and cell-cell signaling networks for therapy and biomarker discovery |
| Funding Source: | CPRIT |
| Role: | Co-PI |
| Date: | 2025 - 2026 |
| Title: | CAR immunotherapy for neuroblastoma |
| Funding Source: | IRG |
| Role: | Co-PI |
| Date: | 2025 - 2026 |
| Title: | Combining redirected and native T cells specificity for osteosarcoma |
| Funding Source: | Sarcoma SPORE Career Enhancement Program |
| Role: | PI |
| Date: | 2025 |
| Title: | Tele-PancFit: Impact of supervised exercise for patients with resectable pancreatic cancer on muscle mass and tumor immune cell infiltration |
| Funding Source: | CPRIT |
| Role: | Co-PI |
| Date: | 2024 - 2029 |
| Title: | attIL12 modified TIL transfer for enhanced tumor infiltration in autologous liposarcoma PDX tumors |
| Funding Source: | NIH/R01 |
| Role: | PI |
| ID: | PA-20-185 |
| Date: | 2024 - 2025 |
| Title: | Reprogramming T Cells to Overcome Pediatric Tumor Resistance |
| Funding Source: | CPRIT MIRA (MDACC-UH) Pilot Project |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | Dual targeting off-the-shelf gamma-delta CAR T cells for precision immunotherapy in neuroblastoma |
| Funding Source: | CPRIT MIRA (MDACC-UH) Pilot Project |
| Role: | PI |
| Date: | 2024 |
| Title: | Translational investigation of metastatic pulmonary pre-seeding cells and their microenvironment through trackable murine chondrocyte-originated osteosarcoma models |
| Funding Source: | MIB Agents |
| Role: | Co-PI |
| Date: | 2024 |
| Title: | Childhood and Adolescent/Young Adult Cancer Research Resource (CARE) |
| Funding Source: | CPRIT |
| Role: | Co-PI |
| Date: | 2024 |
| Title: | Deploying click chemistry against neuroblastoma |
| Funding Source: | Pediatrics Shark Tank |
| Role: | Co-PI |
| Date: | 2023 - 2025 |
| Title: | Bi-specific CAR T cells for AML |
| Funding Source: | Institutional Research Grant Program Award 2023 |
| Role: | PI |
| ID: | 2023-00062775-Y1 |
| Date: | 2023 |
| Title: | Dual targeting CAR T cell therapy for osteosarcoma |
| Funding Source: | Team Connor |
| Role: | PI |
| Date: | 2022 - 2023 |
| Title: | Allogeneic UCB-derived gamma-delta CAR T cells for pediatric malignancies |
| Funding Source: | Hyundai Hope on Wheels |
| Role: | Co-I |
| Date: | 2022 |
| Title: | Off-the-shelf bi-specific CAR T cells for Acute Myeloid Leukemia |
| Funding Source: | Children’s Cancer Research Foundation |
| Role: | PI |
| Date: | 2022 |
| Title: | Gamma delta CAR T cells for Osteosarcoma |
| Funding Source: | Children's Oncology Group, Enzo and Me Pediatric Cancer Foundation Grant for Pediatric Osteosarcoma |
| Role: | CO-I |
| Date: | 2022 |
| Title: | New Approach for Osteosarcoma: Enhancing and Monitoring NK Cell Therapy |
| Funding Source: | NIH |
| Role: | Co-PI |
| Date: | 2021 - 2022 |
| Title: | Gamma-delta T cells for pediatric malignancies |
| Funding Source: | Pediatrics Research--Team Project SCT |
| Role: | Co-PI |
| Date: | 2021 - 2022 |
| Title: | Gamma Delta T cell Therapy for Pediatric Brain Tumors |
| Funding Source: | Matthew Larson Foundation |
| Role: | PI |
| Date: | 2021 |
| Title: | State-of-the-art Pediatric Accelerator for Clinical Trial Excellence, Texas (SPACE TX) |
| Funding Source: | CPRIT |
| Role: | Co-PI |
| Date: | 2020 - 2021 |
| Title: | Targeting Neoantigens in Pediatric Sarcoma |
| Funding Source: | QuadW Foundation |
| Role: | CO-I |
| Date: | 2019 - 2022 |
| Title: | NK cell Therapy for Refractory or Relapsed Osteosarcoma |
| Funding Source: | UTMDACC Multidisciplinary Research Program |
| Role: | CO-I |
| Date: | 2018 - 2020 |
| Title: | Engineering T cells to overcome tumor resistance a |
| Funding Source: | Pediatric Cancer Research Foundation |
| Role: | PI |
| Date: | 2017 - 2020 |
| Title: | Biomanufacturing next generation T cells |
| Funding Source: | National Science Foundation (NSF) |
| Role: | CO-I |
| Date: | 2017 - 2020 |
| Title: | Balancing T-cell function and metabolism for immunotherapy |
| Funding Source: | Department of Defense (DOD) |
| Role: | CO-I |
| Date: | 2017 - 2022 |
| Title: | Qualitative single-cell biomarkers of T-cell biomarkers of T-cell metabolism for predictable immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2017 - 2022 |
| Title: | Dual-targeting Chimeric Antigen Receptor Immunotherapy for Glioblastoma |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2008 |
| Title: | The Kimberly Patterson Fellowship in Leukemia Research |
| Funding Source: | Kimberly Patterson Fellowship |
| Role: | Project Leader |
| Date: | 2007 |
| Title: | Analyses of Hematopoietic Cellular Components Derived from Umbilical Cord Blood-Propagate and Evaluate tumor-specific umbilical cord blood-derived T cells |
| Funding Source: | JP McCarthy Fund |
| Role: | CO-I |
| Date: | 2005 |
| Title: | Evaluating role of CD20-ICK in T Cell persistence and its synergistic role in treating B-lymphoma |
| Funding Source: | City of Hope Lymphoma Spore |
| Role: | Project Leader |
Selected Publications
Professional Educational Materials
- Singh H. Development, generation and implementation of Standard Operating Procedures (SOPs) and Worksheets for GLP and cGMP procedures required for generation of Chimeric Antigen Receptor modified T-cells, 2016.
Patient Reviews
CV information above last modified August 14, 2026